Liberty Health Sciences Issues Stock Options and Shares

/NOT FOR DISSEMINATION IN THE U.S. OR THROUGH U.S. NEWSWIRES/

TORONTO, July 4, 2018 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) ("Liberty" or the "Company") announced that on July 4, 2018 the Board of Directors of the Company granted 450,000 options to purchase common stock to various directors, officers, employees and consultants, at an exercise price of $0.92, for a term of 5 years, pursuant to the Company's incentive stock option plan.

The Company has also completed a settlement of certain debts previously owing to Mr. Henry Froese's company, Thermo Energy Systems Inc., for services performed at the Company's Florida Liberty 360 campus relating to the previously announced retro-fitting and reconstructions efforts. The debt owing was in the amount of US$6,000,000, and the Company and Mr. Froese agreed to settle the debt via an issuance of 10,092,583 common shares of the issuance at a deemed issue price of $0.782 per common share.

About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. operates in cannabis markets focusing on improving the lives of our consumers. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities while keeping consumers' well-being at the forefront of what we do.  Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer.  Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to consumers..

For more information about Liberty please visit www.libertyhealthsciences.com

Neither the Canadian Securities Exchange (the "Exchange") nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Liberty Health Sciences Inc.

For further information: For media inquiries, please contact: Rene Gulliver, Chief Financial Officer, rgulliver@libertyhealthsciences.com